Navigation Links
Replidyne and Cardiovascular Systems Sign Merger Agreement
Date:11/4/2008

Merger to create NASDAQ-listed medical device company focused on developing and commercializing interventional treatment systems for vascular disease Conference call scheduled for Tuesday, November 4, 2008 at 8:30 AM ET

LOUISVILLE, Colo. and ST. PAUL, Minn., Nov. 4 /PRNewswire-FirstCall/ -- Replidyne, Inc. (Nasdaq: RDYN) and Cardiovascular Systems, Inc. (CSI) today announced that they have entered into a definitive merger agreement under which CSI will merge with Replidyne in an all-stock transaction. Under terms of the agreement, Replidyne will issue new shares of its common stock to CSI shareholders whereby former CSI shareholders are expected to own 83 percent of the combined company, and Replidyne shareholders are expected to own 17 percent of the combined company on a fully diluted basis using the treasury stock method, subject to adjustments as described in the merger agreement.

David L. Martin, President and Chief Executive Officer of CSI, said, "Executing this transaction with Replidyne is an expedient way to take our company into the public market and generate a capital infusion for future growth. With an estimated $35 million to $40 million in additional cash and investments from the merger, we can further expand our sales and marketing organization and infrastructure to drive revenue growth and continue to invest in product development for future market expansion."

"After a diligent process of evaluating strategic alternatives carried out over several months, we believe that a merger with CSI presents our investors with a very good opportunity to realize future value," stated Kenneth J. Collins, President and Chief Executive Officer of Replidyne. "Through our process we have evaluated a broad array of oppor
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Replidyne Announces Second Quarter 2008 Results From Operations
2. Replidyne Terminates Faropenem Agreements
3. Replidyne to Report First Quarter 2008 Earnings
4. Replidyne Announces 2007 Fourth Quarter and Full Year Results
5. Replidyne to Report 2007 Fourth Quarter and Year-End Earnings
6. Replidyne to Announce Third Quarter 2007 Earnings
7. Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
8. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
9. CorMatrix Cardiovascular to Present Data on Its Next Generation ECM Technology(TM) at Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington, D.C.
10. Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm
11. Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During Live Case at the Paris Cardiovascular Interventions Course (Francophone) 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Jose, California (PRWEB) September 19, 2014 ... Nanotechnology and its potential to revolutionize the world ... agencies, multinational corporations and small start-ups. The early ... funded research projects largely due to the high ... investments. Government budgets earmarked for this evolving technology ...
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. ... the development of high-value and difficult to manufacture proteins ... presenting at the 21 st Annual NewsMakers in ... . Bertrand Liang , chief executive officer ... development programs and business strategy on Friday, September 26, ...
(Date:9/19/2014)... -- Dublin ... the addition of the  "Micro Market Monitor : ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The ... segments in the chromatography market. The market was ... to reach $2.0 billion by 2019, at a ...
(Date:9/18/2014)... 18, 2014 HealthTronics, Inc ... interventional radiology products and services, announced that a ... and cryoablation) versus external beam radiotherapy (EBRT) is ... American Urological Association (MAAUA) Annual Meeting in Baltimore, ... Effectiveness of Cryosurgery and External Beam Radiation as ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... S.C., Dec. 1 Collexis Holdings, Inc.,(OTC ... semantic search and,knowledge discovery software, announced today ... association, to promote BiomedExperts.com,to the association,s 200+ ... as the primary professional network for,BioFlorida, helping ...
... company aided in the research of vein treatment methods led by Dr. ... develop a new medical device, which he will present this summer to ... ... 1, 2008-- A gift from a California company aided in the research ...
... Encorium Group, Inc.,(Nasdaq: ENCO ), a ... over 30 countries for many of the world,s leading,pharmaceutical ... it received a letter from Nasdaq stating that since ... period ended September 30, 2008 as of the,date of ...
Cached Biology Technology:BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 2BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 3BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 4Gift Aids Professor's Research into Vein Treatment 2Gift Aids Professor's Research into Vein Treatment 3Gift Aids Professor's Research into Vein Treatment 4Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing 2Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing 3
(Date:9/18/2014)... researchers have developed a unique method to use microbes ... rural areas. , The first microbe-powered, self-sustaining wastewater ... way to clean up waste from large farming operations ... , Professor Haluk Beyenal and graduate student Timothy Ewing ... the system in the online edition of Journal ...
(Date:9/18/2014)... into the Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne ... similar to that caused by Ebolavirus, has identified new ... the potential to lead to novel targets for therapeutic ... reported in a paper published today in the journal ... the Texas Biomedical Research Institute and their colleagues, represents ...
(Date:9/18/2014)... times it,s demonstrated, it,s still hard to envision ... by using a signaling system called "quorum sensing," ... suit their population. In short, some bacteria "know" ... accordingly. , Once the population of quorum-sensing bacteria ... to pathogenic, or from unhelpful to helpful. The ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Research milestone in CCHF virus could help identify new treatments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... a paper published in the October 2011 issue of ... researchers at Columbia University Medical Center led by Stephen ... photoreceptors in a mouse model for retinitis pigmentosa (RP) ... a heterogeneous disorder characterized by progressive degeneration of rod ...
... Calif., Sept. 30, 2011 A glucosamine-like dietary supplement ... according to a UC Irvine study. UCI,s Dr. ... N-acetylglucosamine (GlcNAc), which is similar to but more effective ... function of abnormal T-cells that in MS incorrectly direct ...
... Perez Olsen, Ph.D., a Weintraub Scholar in the Basic ... the recipient of the National Institutes of Health Director,s ... first group of 10 junior U.S. investigators to receive ... million to support their research over a five-year period; ...
Cached Biology News:Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 2Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 3Glucosamine-like supplement suppresses multiple sclerosis attacks 2Hutchinson Center scientist wins first NIH Director's Early Indpendence Award 2
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... microRNA Microarray contains all known fish ...
... unique quantitative and qualitative capabilities of the ... LC/MS/MS Systems with the new Tempo nano ... a rapid solution for high sensitivity validation ... extensive sample preparation with high instrument selectivity ...
... of Agilent analytical solutions is the 6890N ... (LAN) allows you to share business and ... decision making. Just as its 6890 GC ... and performance needed for research and method ...
... The 6820 GC system combines world-class performance ... QA/QC software, Agilents world-renowned support and columns, ... and supplies--a combination that lets you reach ... based on dependable data. The Agilent 6820 ...
Biology Products: